AURA Aura Biosciences, Inc.
USHealthcareAs of 2026-08-24
Why AURA matters now
Aura Biosciences, Inc. (AURA) is a US stock in Healthcare. The latest InvestLog snapshot shows $7.90 with +1.28% on the session and $817.1M in market capitalization; recent performance reads 1-month -14.21% and YTD +16.33%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-33.7M, and EPS of $-0.50. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -22.5%.
The latest indexable market news headline is "Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $17.00; recent insider activity includes Gibney Anthony S filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.99
P/S
0.00
EV/EBITDA
-3.05
DCF Value
$0.67
FCF Yield
-22.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-78.1%
ROA
-81.6%
ROIC
-95.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-33.7M | $-0.50 |
| Q4 2025 | $0.00 | $-25.6M | $-0.40 |
| FY 2025 | $0.00 | $-106.2M | $-1.76 |
| Q3 2025 | $0.00 | $-26.1M | $-0.40 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$17.00
Target (Median)
$17.00
Target Range
$17.00 - $17.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.39
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.